Recombinant Human CXCL9 Protein，His

CXCL9, also known as MIG (Monokine Induced by Gamma Interferon), is a chemokine that plays a crucial role in immune responses, particularly in recruiting T cells and natural killer (NK) cells to sites of inflammation and infection. Its primary function is to bind to the CXCR3 receptor, which is upregulated on activated T cells and NK cells, facilitating their migration toward areas of CXCL9 expression. Research has increasingly focused on CXCL9 due to its potential therapeutic applications in various diseases, including cancer, autoimmune disorders, and viral infections. In cancer immunotherapy, CXCL9 is of great interest because it can enhance T cell infiltration into tumors, potentially improving the efficacy of immune checkpoint inhibitors. Additionally, its role in modulating the immune microenvironment makes it a potential target for drug development. Recombinant CXCL9 protein has been investigated for its ability to stimulate immune responses in preclinical and clinical studies. Understanding the mechanisms by which CXCL9 influences immune cell behavior and its interactions with other chemokines and cytokines is essential for developing effective therapies. As such, the production and characterization of recombinant CXCL9 allow researchers to explore its biological functions further and assess its clinical relevance in various therapeutic contexts. Overall, the ongoing research into CXCL9 and its recombinant protein form offers promising insights into the modulation of immune responses and the advancement of targeted therapies in immunology and oncology.